NCT00975481

A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users

A Randomized, Double-Blind, Placebo- And Active-Controlled Single-Dose, Crossover Study To Evaluate The Abuse Potential Of Single Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam).

Detailed description

The main purpose for this study is to determine whether dimebon exhibits abuse potential.

Conditions

• Alzheimer's Disease
• Huntington's Disease

Interventions

Type	Name	Description
DRUG	dimebon	Oral tablet; 20 mg dimebon, single dose
DRUG	dimebon	Oral tablet; 40 mg dimebon, single dose
DRUG	dimebon	Oral tablet; 60 mg dimebon, single dose
DRUG	placebo	Oral tablet or capsule; placebo, single dose
DRUG	alprazolam	Oral capsule; 1 mg alprazolam, single dose
DRUG	alprazolam	Oral capsule; 3 mg alprazolam, single dose

Timeline

• Start date: 2009-10-01
• Primary completion: 2010-02-01
• Completion: 2010-02-01
• First posted: 2009-09-11
• Last updated: 2013-04-02
• Results posted: 2013-04-02